Key facts
- This page summarizes Dean J. Mitchell's Form 4/A filing for ImmunoGen, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Dec 2023, 19:00.
Dean J. Mitchell - 22 Sep 2023 Form 4/A Insider Report for ImmunoGen, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 22 Sep 2023
- Net transaction value
- +$147,000
- SEC form
- 4/A
- Accepted by SEC
- 19 Dec 2023, 19:00:22 UTC
- Original report date
- 26 Sep 2023
- Prior SEC filing
- 16 Jun 2023
- Next SEC filing
- 12 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Dean J. Mitchell filed Form 4/A for ImmunoGen, Inc. on 19 Dec 2023.
Change
- Previous filing in this sequence was filed on 16 Jun 2023.
- Current net transaction value: +$147,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMGN
transaction
Common Stock
Options Exercise
- Transaction value
- $147,000
- Shares
- +10,000
- Change %
- +11%
- Price
- $14.70
- Shares after
- 103,000
- Date
- 22 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Due to clerical error, this amendment to Form 4 is being filed to correct the number of shares beneficially owned following the reported transaction.